(CGC) Canopy Growth - Ratings and Ratios
Cannabis, Hemp, Extracts, Edibles, Oils, Beverages, Concentrates
CGC EPS (Earnings per Share)
CGC Revenue
Description: CGC Canopy Growth
Canopy Growth Corporation is a multinational cannabis company operating in Canada, Germany, and Australia, with a diverse portfolio of cannabis, hemp, and related products. The company operates through four business segments: Canada Cannabis, International Markets Cannabis, Storz & Bickel, and This Works, offering a range of products including dried flower, extracts, edibles, vapes, and oils under various brands.
From a product perspective, Canopy Growth has a broad portfolio with multiple brands such as Tweed, 7ACRES, and Wana, catering to different market segments. The companys product offerings are diversified across various categories, including medicinal and recreational cannabis products. To evaluate the companys performance, key performance indicators (KPIs) such as revenue growth, gross margin, and cannabis production capacity can be considered.
Analyzing the companys financials, the market capitalization stands at $260.84M USD, indicating a relatively small-cap stock. The absence of a price-to-earnings (P/E) ratio suggests that the company is currently unprofitable. Return on Equity (RoE) is significantly negative at -112.71%, indicating substantial losses. To further assess the companys financial health, KPIs such as cash burn rate, operating expenses as a percentage of revenue, and debt-to-equity ratio can be examined.
From an operational perspective, Canopy Growths production capacity, cultivation costs, and product pricing strategy are crucial factors influencing its profitability. The companys ability to expand its market share, both domestically and internationally, will be critical in driving future growth. Key metrics to monitor include the companys cannabis production volume, average selling price (ASP) per gram, and the proportion of revenue from medical versus recreational cannabis sales.
CGC Stock Overview
| Market Cap in USD | 472m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2014-04-04 |
CGC Stock Ratings
| Growth Rating | -90.9% |
| Fundamental | 11.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -76.2% |
| Analyst Rating | 2.50 of 5 |
CGC Dividends
Currently no dividends paidCGC Growth Ratios
| Growth Correlation 3m | 46.2% |
| Growth Correlation 12m | -77.2% |
| Growth Correlation 5y | -96.2% |
| CAGR 5y | -65.30% |
| CAGR/Max DD 3y | -0.67 |
| CAGR/Mean DD 3y | -0.74 |
| Sharpe Ratio 12m | -1.81 |
| Alpha | -87.41 |
| Beta | 0.771 |
| Volatility | 132.46% |
| Current Volume | 14086.7k |
| Average Volume 20d | 18021.5k |
| Stop Loss | 1.2 (-13.7%) |
| Signal | 0.35 |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-510.9m TTM) > 0 and > 6% of Revenue (6% = 16.4m TTM) |
| FCFTA -0.20 (>2.0%) and ΔFCFTA 2.73pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 74.86% (prev 66.56%; Δ 8.30pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.14 (>3.0%) and CFO -124.3m > Net Income -510.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.07 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (188.3m) change vs 12m ago 137.7% (target <= -2.0% for YES) |
| Gross Margin 20.50% (prev 26.79%; Δ -6.29pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 24.97% (prev 22.33%; Δ 2.64pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -4.21 (EBITDA TTM -409.0m / Interest Expense TTM 106.9m) >= 6 (WARN >= 3) |
Altman Z'' -46.18
| (A) 0.23 = (Total Current Assets 303.4m - Total Current Liabilities 98.7m) / Total Assets 904.7m |
| (B) -12.13 = Retained Earnings (Balance) -10.97b / Total Assets 904.7m |
| warn (B) unusual magnitude: -12.13 — check mapping/units |
| (C) -0.41 = EBIT TTM -450.6m / Avg Total Assets 1.10b |
| (D) -5.11 = Book Value of Equity -2.13b / Total Liabilities 415.7m |
| Total Rating: -46.18 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 11.28
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield -21.69% = -5.0 |
| 3. FCF Margin -64.58% = -7.50 |
| 4. Debt/Equity 0.63 = 2.31 |
| 5. Debt/Ebitda -0.75 = -2.50 |
| 6. ROIC - WACC -55.90% = -12.50 |
| 7. RoE -98.58% = -2.50 |
| 8. Rev. Trend -80.89% = -4.04 |
| 9. Rev. CAGR -16.35% = -2.50 |
| 10. EPS Trend 0.74% = 0.02 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of CGC shares?
Over the past week, the price has changed by +2.96%, over one month by +6.92%, over three months by -4.14% and over the past year by -71.69%.
Is Canopy Growth a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CGC is around 0.49 USD . This means that CGC is currently overvalued and has a potential downside of -64.75%.
Is CGC a buy, sell or hold?
- Strong Buy: 0
- Buy: 2
- Hold: 4
- Sell: 1
- Strong Sell: 3
What are the forecasts/targets for the CGC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 3.8 | 173.4% |
| Analysts Target Price | 3.8 | 173.4% |
| ValueRay Target Price | 0.5 | -61.2% |
Last update: 2025-09-05 04:37
CGC Fundamental Data Overview
CCE Cash And Equivalents = 143.6m CAD (Cash And Short Term Investments, last quarter)
P/S = 1.7153
P/B = 1.3062
Beta = 2.083
Revenue TTM = 273.4m CAD
EBIT TTM = -450.6m CAD
EBITDA TTM = -409.0m CAD
Long Term Debt = 289.0m CAD (from longTermDebt, last quarter)
Short Term Debt = 18.9m CAD (from shortTermDebt, last quarter)
Debt = 307.9m CAD (Calculated: Short Term 18.9m + Long Term 289.0m)
Net Debt = 201.6m CAD (from netDebt column, last quarter)
Enterprise Value = 813.9m CAD (649.6m + Debt 307.9m - CCE 143.6m)
Interest Coverage Ratio = -4.21 (Ebit TTM -450.6m / Interest Expense TTM 106.9m)
FCF Yield = -21.69% (FCF TTM -176.6m / Enterprise Value 813.9m)
FCF Margin = -64.58% (FCF TTM -176.6m / Revenue TTM 273.4m)
Net Margin = -186.9% (Net Income TTM -510.9m / Revenue TTM 273.4m)
Gross Margin = 20.50% ((Revenue TTM 273.4m - Cost of Revenue TTM 217.4m) / Revenue TTM)
Tobins Q-Ratio = -0.38 (set to none) (Enterprise Value 813.9m / Book Value Of Equity -2.13b)
Interest Expense / Debt = 3.16% (Interest Expense 9.74m / Debt 307.9m)
Taxrate = 21.0% (US default)
NOPAT = -450.6m (EBIT -450.6m, no tax applied on loss)
Current Ratio = 3.07 (Total Current Assets 303.4m / Total Current Liabilities 98.7m)
Debt / Equity = 0.63 (Debt 307.9m / last Quarter total Stockholder Equity 489.0m)
Debt / EBITDA = -0.75 (Net Debt 201.6m / EBITDA -409.0m)
Debt / FCF = -1.74 (Debt 307.9m / FCF TTM -176.6m)
Total Stockholder Equity = 518.3m (last 4 quarters mean)
RoA = -56.48% (Net Income -510.9m, Total Assets 904.7m )
RoE = -98.58% (Net Income TTM -510.9m / Total Stockholder Equity 518.3m)
RoCE = -55.82% (Ebit -450.6m / (Equity 518.3m + L.T.Debt 289.0m))
RoIC = -49.09% (NOPAT -450.6m / Invested Capital 918.0m)
WACC = 6.81% (E(649.6m)/V(957.5m) * Re(8.86%)) + (D(307.9m)/V(957.5m) * Rd(3.16%) * (1-Tc(0.21)))
Shares Correlation 3-Years: -23.26 | Cagr: -8.01%
Discount Rate = 8.86% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -176.6m)
Revenue Correlation: -80.89 | Revenue CAGR: -16.35%
Rev Growth-of-Growth: 26.64
EPS Correlation: 0.74 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 122.5
Additional Sources for CGC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle